MaxCyte Inc., a leading cell therapy and gene editing company, announced Thursday that it has acquired SeQure Dx, a specialized gene editing firm, in a deal worth up to $7 million. The move is aimed at enhancing MaxCyte’s scientific capabilities and boosting revenue growth in the expanding cell and gene therapy industry.
Under the agreement, MaxCyte paid $4.5 million in cash at closing for SeQure Dx’s entire issued share capital on a cash-free, debt-free basis. An additional $2.5 million may be paid if SeQure meets certain revenue targets.
SeQure Dx’s Business Model and Financial Performance
In 2024, SeQure Dx generated $1.7 million in revenue but reported a $6.5 million loss, based on unaudited results from Jan. 1 to Nov. 30. Despite these figures, MaxCyte expects SeQure’s financial performance to improve, citing the firm’s March 2024 transition from an assay development and licensing business to a contract service provider.
MaxCyte CEO: Deal Will Drive Innovation in Cell and Gene Therapies
MaxCyte CEO Maher Masoud said the acquisition aligns with the company’s long-term growth strategy.
